X0206 3 2015-08-05 0 0001631650 Aimmune Therapeutics, Inc. AIMT 0001594912 Foresite Capital Management II, LLC 101 CALIFORNIA STREET SUITE 4100 SAN FRANCISCO CA 94111 0 0 1 0 0001594914 Foresite Capital Fund II, L.P. 101 CALIFORNIA STREET SUITE 4100 SAN FRANCISCO CA 94111 0 0 1 0 0001581754 Tananbaum James B. 3052 PACIFIC AVENUE SAN FRANCISCO CA 94115 0 0 1 0 Series B Convertible Preferred Stock 0.00 Common Stock 3775400 I By: Foresite Capital Fund II, L.P. The Series B Convertible Preferred Stock automatically converts into shares of Issuer's Common Stock on a 1:1 basis immediately prior to the completion of Issuer's initial public offering. The expiration date is not relevant to the conversion of these securities. Shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the Designated Filer and general partner of FCF II, may be deemed to have the sole voting and dispositive power over the shares of Issuer's Series B Convertible Preferred Stock (the "Shares"). James Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM II, may be deemed to have the sole voting and dispositive power over the Shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its partners and Mr. Tananbaum disclaims beneficial ownership of any of the Shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its partners or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. FORESITE CAPITAL MANAGEMENT II, LLC, By: /s/ Dennis D. Ryan, Chief Financial Officer 2015-08-05 FORESITE CAPITAL FUND II, L.P., By: Foresite Capital Management II, LLC, Its General Partner, By: /s/ Dennis D. Ryan, Chief Financial Officer 2015-08-05 /s/ James B. Tananbaum 2015-08-05